Prac recommendations
Prac recommendations has been studied in 1 paper since 2026: 1 observational study in people; 1 in the past year. The newest paper, Feb 10, 2026: “The Impact of PRAC EMA/AIFA Recommendations on the Prescriptions of JAKi and b-DMARDs: Preliminary Results of the Survey from 21 Rheumatological Italian Centers Affiliated with CReI”.
1 paper studies it3 findingsUpdated
See all 1 papers on prac recommendations
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“Notably, upadacitinib utilization remained stable despite regulatory restrictions.”
None of its findings points the other way.
- 1 lab in 1 country
- Humans1
What did studies of prac recommendations find?
2Studies of prac recommendations measured 2 outcomes: upadacitinib and statins.
Upadacitinib
no changein humans1
1 study
Upadacitinib
no changein humans1
Prac recommendations were not clearly linked with upadacitinib in humans (rheumatoid arthritis).
“Notably, upadacitinib utilization remained stable despite regulatory restrictions.”
Humansrheumatoid arthritis
Journal of personalized medicine
Statins
upin humans1
1 study
Statins
upin humans1
Prac recommendations are linked with higher statins in humans (rheumatoid arthritis) (8.25% vs. 11.1%).
“and increased statin use (8.25% vs. 11.1%; p = 0.05).”
Humansrheumatoid arthritisn = 4,376
Journal of personalized medicine
What is prac recommendations linked with?
1Studies link prac recommendations with myocardial infarction.
Myocardial infarction
downin humans1
1 study
Myocardial infarction
downin humans1
Prac recommendations are linked with a lower risk of myocardial infarction in humans (rheumatoid arthritis) (0.90% vs. 0.47%).
“The post-PRAC cohort showed a significant reduction in myocardial infarction incidence (0.90% vs. 0.47%; p = 0.02)”
Humansrheumatoid arthritisn = 4,376
Journal of personalized medicine